Changes in Beneficial Ownership · 4
Assembly Biosciences, Inc.
ASMBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-04
- Issuer
- ASSEMBLY BIOSCIENCES, INC.
- Issuer CIK
- 0001426800
- Trading symbol
- ASMB
Reporting owner 1
- Name
- ALTIG ANTHONY E
- Reporting owner CIK
- 0001215907
- Relationship
- Director
- Address
- C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 24.11 | 2026-06-04 | A · Form 4 | 8,000 | A | 0 | [F1] | 2036-06-04 | Common Stock | 8,000 | 8,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.↩ 1
Signature 1
- Signed
- /s/ John O. Gunderson, as Attorney-in-Fact
- Date
- 2026-06-05
Company context
In October 2023, Assembly Bio and Gilead entered into a 12-year collaboration to advance the research and development of novel antiviral therapies. Under the collaboration, Gilead has an option to obtain exclusive rights to each of Assembly Bio’s current and future programs, and Assembly Bio is eligible to receive collaboration extension fees, option fees, milestone payments and royalties. Following Gilead’s exercise of an option, Assembly Bio has the right to elect to share costs and profits in the U.S., as well as certain co-promotion rights for future programs.